antibody-drug

Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd). Trastuzumab deruxtecan has an improved effect on the treatment of HER2-positive breast cancer and gastric cancer.

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Datopotamab deruxtecan (DS-1062) is a trophoblast cell surface antigen 2 (TROP2)-targeted antibody-drug conjugate (ADC) with antitumor activity. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Izeltabart Tapatansine (IMGC-936) is a CHO-expressing humanized next-generation medetonin-based ADC compound targeting ADAM9-expressing tumors, and exhibits cytotoxicity against ADAM9-positive human tumor cell lines for cancer research.

Telisotuzumab vedotin (ABBV-399) is an ADC compound targeting c-Met with antitumor activity, used for research in recurrent squamous cell lung cancer.

Patritumab deruxtecan (HER3-DXd) is an antibody-drug coupling (ADC) targeting HER3 consisting of a fully humanized anti-HER3 IgG1 monoclonal antibody linked via a cleavable tetrapeptide linker to a topoisomerase I inhibitor payload (an ezetiocan derivative, DXd) for the study of non-small cell lung cancer (NSCLC).

Becotatug (JMT-101) is an IgG1 antibody targeting EGFR, which can be conjugated to Afatinib and Osimertinib, serving as a synthetic antibody-drug conjugate (ADC) [1].

Sirtratumab vedotin (ASG15-ME) is an antibody-drug conjugate (ADC) that links a SLITRK6-specific human gamma 2 antibody (Igγ2) to the microtubule disruption agent monomethyl auristatin E (MMAE) through a protease-cleavable linker [1].

Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].

Lorvotuzumab mertansine is an antibody-drug conjugate (ADC) that can be used in life science related research. The CAS number is 1008106-64-6.

Praluzatamab ravtansine is an antibody-drug conjugate (ADC) that can be used in life science related research. The CAS number is 2145115-85-9.

Trastuzumab duocarmazine ((vic)-Trastuzumab duocarmazine) is an ADC targeting HER2, cleaved by histone B within tumor cells for selective targeting, exhibiting antitumor activity and applicable in cancer research, particularly for uterine and ovarian sarcomas [1].

Cofetuzumab pelidotin (PF-06647020) is an antibody-drug conjugate (ADC) targeting PTK7, composed of the humanized anti-PTK7 monoclonal antibody (hu6M024, IgG1) linked to the auristatin-based microtubule inhibitor payload, auristatin-0101 (Aur0101), via a cleavable valine-citrulline (vc)-based linker. This compound exhibits a drug-to-antibody ratio (DAR) of 4 and selectively binds to cell-surface PTK7 with an EC50 of 1153 pM as determined by flow cytometry. Cofetuzumab pelidotin holds promise for the study of solid tumors [1] [2] [3].

Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted antibody-drug conjugate (ADC). This compound comprises a pyrrolobenzodiazepine (PBD) dimer and the active payload SG3249.

Cantuzumab ravtansine (IMGN242; huC242-DM4), an antibody-drug conjugate (ADC), comprises the humanized monoclonal antibody huC242 covalently bonded through a disulfide linkage to the cytotoxic agent DM4 (DM4), demonstrating extensive antitumor effectiveness across various CanAg-positive human tumor xenografts [1] [2].

Enfortumab is a monoclonal antibody against Nectin-4.Enfortumab can be used to synthesize antibody-drug couplings (enfortumab vedotin) and can also be used in conjunction with platinum compounds to study uroepithelial cancers.

Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.

Vorsetuzumab mafodotin, a humanized anti-CD70 monoclonal antibody, conjugates with monomethyl auristatin F (MMAF) through Seattle Genetics' proprietary antibody-drug conjugate (ADC) technology. This affinity allows targeting of various solid tumors and cancers such as renal cell carcinoma, pancreatic, ovarian, and lung cancers, alongside multiple myeloma and several forms of non-Hodgkin lymphoma, all of which express CD70.

Naratuximab emtansine (IMGN529) is a CD37-targeted antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody linked to the microtubule-disrupting agent DM1. This compound demonstrates high affinity and specificity to CD37, facilitating the internalization, processing, and intracellular release of DM1. The functional activity of DM1 enables it to induce cell cycle arrest and apoptosis by disrupting microtubule assembly.

Anti-SEZ6 Antibody (SC17) is a monoclonal IgG1 antibody targeting SEZ6. It is utilized in the synthesis of antibody-drug conjugate (ADC) products, such as ABBV-011.

ABBV-154 is an anti-TNF antibody-drug conjugate (ADC) composed of the humanized antibody Adalimumab linked to a glucocorticoid receptor modulator. It is employed in the research of rheumatoid arthritis, Crohn's disease, and polymyalgia rheumatica.

Vobramitamab, a humanized B7-H3 monoclonal antibody (mAb), is conjugated to the prodrug seco-DUBA through a cleavable linker, creating the antibody-drug conjugate (ADC) known as MGC018 [1].

Izeltabart (IMGC-936) is a Maytansinoid-based Antibody-Drug Conjugate (ADC) that specifically targets ADAM9. It consists of a high-affinity humanized antibody conjugated site-specifically to DM21-C, a linker-payload that combines a microtubule-disrupting Maytansinoid with a stable tripeptide linker, maintaining a drug-to-antibody ratio of approximately 2.0. Izeltabart demonstrates cytotoxicity against ADAM9-expressing human tumor cell lines and possesses significant antitumor efficacy in xenograft tumor models [1].

Upifitamab rilsodotin (XMT-1536), an antibody-drug conjugate, specifically targets NaPi2b and is utilized in cancer research, particularly in studies related to ovarian cancer [1] [2].